<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **MYEL-D (1 of 2)**  
External request: Submission from Takeda Pharmaceutical Company Limited.  
Request the NCCN Multiple Myeloma Panel to review the data on the use of ixazomib in combination with lenalidomide and dexamethasone as first-line therapy for transplant-ineligible patients with multiple myeloma. | Based on the data in the noted reference and discussion, the panel added the combination ixazomib/lenalidomide/dexamethasone as a preferred regimen option for primary therapy.  
| **MYEL-D (1 of 2)**  
Internal request: Change in category of bortezomib/len/dex for primary treatment of both transplant-eligible and ineligible from 2A to category 1. | Based on the data in the noted reference the NCCN Category of Evidence has been changed from a category 2A to a category 1.  
| **MYEL-D (2 of 2)**  
External request: Submission from: Bristol-Myers Squibb Company.  
Request the NCCN Multiple Myeloma Panel to consider recommending elotuzumab in combination with lenalidomide and dexamethasone in the NCCN Multiple Myeloma Guidelines as a Category 1 preferred regimen for previously treated multiple myeloma. | Based on the data in the noted reference and discussion, the Panel added elotuzumab in combination with lenalidomide and dexamethasone as a preferred regimen option for previously treated multiple myeloma.  
| **MYEL-D (2 of 2)**  
External request: Submission from: Bristol-Myers Squibb Company.  
Panel consensus supported not including this combination at this time. | Panel consensus supported not including this combination at this time.  
Jakubowiak A, Offidani M, Pegourie B, et al. A randomized, open-label, | 0 15 0 11 |
<table>
<thead>
<tr>
<th>Squibb Company.</th>
<th>Phase 2 study of bortezomib and dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma. Oral presentation at: The 20th Congress of the European Hematology Association (EHA) Annual Meeting; June 11-14, 2015; Vienna, Austria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MYEL-D (2 of 2)</strong>&lt;br&gt;External request:&lt;br&gt;Submission from Takeda Pharmaceutical Company Limited.</td>
<td>Based on the data in the noted reference and discussion, the panel added ixazomib/lenalidomide/dexamethasone as a preferred regimen option for previously treated multiple myeloma. Moreau P, Masszi T, Grzasko N, et al. Ixazomib, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRd), significantly extends progression-free survival</td>
</tr>
</tbody>
</table>
on the use of ixazomib in combination with lenalidomide and dexamethasone as therapy for patients with previously treated multiple myeloma.

(PFS) for patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): The Phase 3 TOURMALINE-MM1 Study (NCT01564537). Blood 2015;126(21):abstract 727; data from ASH 2015 Annual Meeting abstract.

**MYEL-D (2 of 2)**

**External request:** Submission from Takeda Pharmaceutical Company Limited. Request the NCCN Multiple Myeloma Panel to review the data on the use of ixazomib as a single agent or in combination with dexamethasone as therapy for patients with previously treated multiple myeloma.

Based on the data in the noted references and discussion, the panel added ixazomib ± dexamethasone as a preferred regimen option for previously treated multiple myeloma.


| 15 | 0 | 0 | 11 |